LFWD trades 49.3% below Wall Street's consensus target of $10.75.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LFWD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Lifeward Ltd. (LFWD) has a Wall Street consensus price target of $10.75, based on estimates from 5 covering analysts. With the stock currently trading at $7.20, this represents a potential upside of +49.3%. The company has a market capitalization of $12M.
Analyst price targets range from a low of $8.50 to a high of $13.00, representing a 42% spread in expectations. The median target of $10.75 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LFWD trades at a trailing P/E of -0.4x. Analysts expect EPS to grow +82.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EKSOEkso Bionics Holdings, Inc. | $54M | $22.20 | $6.00 | -73.0% | Buy | — | 4 |
IRBTiRobot Corporation | $2M | $0.05 | — | — | — | — | — |
MBOTMicrobot Medical Inc. | $81M | $1.77 | $5.50 | +210.7% | Buy | — | 3 |
GMEDGlobus Medical, Inc. | $11.6B | $86.25 | $109.50 | +27.0% | Buy | 18.2x | 36 |
NVCRNovoCure Limited | $1.8B | $15.43 | $33.00 | +113.9% | Buy | — | 15 |
SYKStryker Corporation | $127.4B | $332.31 | $387.46 | +16.6% | Buy | 22.2x | 51 |
MDTMedtronic plc | $104.0B | $80.98 | $95.80 | +18.3% | Buy | 13.6x | 51 |
ABTAbbott Laboratories | $163.4B | $93.82 | $126.00 | +34.3% | Buy | 17.1x | 41 |
INVAInnoviva, Inc. | $1.7B | $23.57 | $37.00 | +57.0% | Buy | 6.6x | 10 |
ISRGIntuitive Surgical, Inc. | $143.6B | $404.27 | $597.78 | +47.9% | Buy | 38.7x | 55 |
Quick answers to the most common questions about buying LFWD stock.
The consensus Wall Street price target for LFWD is $10.75, representing 49.3% upside from the current price of $7.2. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LFWD has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $10.75 implies 49.3% upside from current levels.
LFWD's current price is $7.2 with a consensus target of $10.75 (49.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $13 for LFWD, while the most conservative target is $8.5. The consensus of $10.75 represents the median expectation. These targets typically reflect 12-month expectations.
LFWD is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LFWD stock forecast based on 5 Wall Street analysts shows a consensus price target of $10.75, with estimates ranging from $8.5 (bear case) to $13 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on LFWD, with a "Buy" consensus rating and $10.75 price target (49.3% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LFWD analyst price targets range from $8.5 to $13, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.75 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.